KR920700684A - t-PA pro의 안정화 - Google Patents
t-PA pro의 안정화Info
- Publication number
- KR920700684A KR920700684A KR1019910700935A KR910700935A KR920700684A KR 920700684 A KR920700684 A KR 920700684A KR 1019910700935 A KR1019910700935 A KR 1019910700935A KR 910700935 A KR910700935 A KR 910700935A KR 920700684 A KR920700684 A KR 920700684A
- Authority
- KR
- South Korea
- Prior art keywords
- mmol
- acid
- sodium citrate
- pharmaceutical
- pharmaceutical formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (21)
- 다음 화합물들, 즉 a)아스코르빈산, b)EDTA, c)다음 구조식의 아미노 화합물, R1R2N-R-X의 식중, X는 SO3H, CH(NH2)-CO2H, CO2H, H, NH2또는 OH, R은 C1-9-알킬렌 C3-6, 사이클로알킬렌 또는 벤질리덴, R1및 R2는 각각 H또는 C1-3알킬, d)구아니디노부티르산, e) 디메틸바이구아나이드, f)아르기닌, g) 글루코사민, 플럭토스, h)피리미딘 뉴클레오시드 및 피리미딘 뉴클레오타이드, i) 하나 이상의 하이드록실, 케토 및/ 또는 또다른 카복실 그룹으로 치환된 카복실산류로 구성된 그룹에서 선택된 최소한 하나의 화합물 및 시트르산염을 함유하는 것을 특징으로 하는 pH가 4.5-6이고 효소활성이 최소한 0.1MU/ml인 비글리코실화 t-PA의 제약학적 제제.
- 제1항에 있어서, 아미노 화합물이 타우린, 4-아미노부탄올-1, 5-아미노펜탄올-1,6-아미노헥산올-1, 1,9-디아미노노난, 1,8-디아미노옥탄, 1,7-디아미노헵탄, 1,6-디아미노헥산, 1,5-디아미노펜탄, 1,4-아미노부탄, 또는 1,3-아미노프로판, 라이신, 오르니틴, 8-아미노옥탄산, 7-아미노헵탄산, ε-아미노카프론산, δ-아미노발레린산, γ-아미노부티르산, 트라넥사민산 또는 p-아미노메틸벤조산인 것을 특징으로 하는 의약 제조물.
- 제1항에 있어서, 하나이상의 하이드록실, 케토 및 또는 또 다른 카복실 그룹으로 치환된 카복실산의 말산, 젖산, 푸마르산 또는 2-옥소글루타르산인 것을 특징으로 하는 제약학적 제제.
- 제1항에 있어서, 하나 이상의 아미노산을 부가적으로 함유하는 것을 특징으로 하는 제약학적 제제.
- 제1항 내지 제4항중 어느 한 항에 있어서, 시트르산염 농도가 5-100mmol/l, 바람직하게는 50mmol/l인 것을 특징으로하는 제약학적 제제.
- 제1항 내지 제5항중 어느 한 항에 있어서, 염화물 이온을 부가적으로 함유하는 것을 특징으로 하는 제약학적 제제.
- 제1항에 있어서, 50mmol/l의 시트르산나트륨(pH6), 및 0.1-1mmol/l, 바람직하게 0.2-0.3mol/l의 아스코르빈산을 함유하는 것을 특징으로 하는 제약학적 제제.
- 제1항에 있어서, 50mmol/l의 시트르산나트륨(pH6), 및 1-200mmol/l, 바람직하게 10-100mmol/l의 EDTA를 함유하는 것을 특징으로 하는 제약학적 제제.
- 제1항에 있어서, 50mmol/l의 시트르산나트륨(pH6), 및 0.1-0.5mmol/l, 바람직하게 0.1-0.3mol/l의 타우린을 함유하는 것을 특징으로 하는 제약학적 제제.
- 제1항에 있어서, 50mmol/l의 시트르산나트륨/HCI(pH6), 및 0.5-20mmol/l,라이신, 오르니틴, 8-아미노옥탄산, 7-아미노헵탄산, ε-아미노카프론산, δ-아미노발레린산.-아미노부티르산, 트라넥사민산 또는 p-아미노케틸벤조산을 함유하는 것을 특징으로 하는 제약학적 제제.
- 제1항에 있어서, 50mmol/l의 시트르산나트륨(pH6), 및 10-100mmol/l의 4-아미노부탄올-1,5-아미노펜탄올-1,6-아미노헥산올-1, 1,3-디아미노프로판, 1,4-디아미노부탄, 1,5-디아미노펜탄, 1,6-디아미노헥산, 1,7-디아미노헵탄, 1,8-디아네노옥탄 또는 1,9-디아미노노난을 함유하는 것을 특징으로 하는 제약학적 제제.
- 제1항에 있어서, 50mmol/l의 시트르산나트륨/HCI (pH6), 및 10-200mmol/l, 바람직하게 50-100mmol/l의 구아니디노부티르산 또는 아르기닌을 함유하는 것을 특징으로 하는 제약학적 제제.
- 제1항에 있어서, 50mmol/l의 시트르산나트륨/HCI (pH6), 및 50-400mmol/l, 바람직하게 100-300mmol/l의 디메틸비구아나이드를 함유하는 것을 특징으로 하는 제약학적 제제.
- 제1항에 있어서, 50mmol/l의 시트르산나트륨/HCI (pH6), 및 1-500mmol/l, 바람직하게 10-300mmol/l의 글루코사민 또는 프럭토스를 함유하는 것을 특징으로 하는 제약학적 제제.
- 제1항에 있어서, 50mmol/l의 시트르산나트륨/HCI (pH6), 및 1-300mmol/l, 바람직하게 10-300mmol/l의 티미딘, 시토신 또는 우리딘을 함유하는 것을 특징으로 하는 제약학적 제제.
- 제1항에 있어서, 50mmol/l의 시트르산나트륨(pH6), 및 0.001-1mmol/l, 바람직하게 0.1-0.5mmol/l의 말산, 젖산, 푸마르산 또는 2-옥소글루타르산을 함유하는 것을 특징으로 하는 제약학적 제제.
- 제1항에 있어서, 50mmol/l의 시트르산나트륨(pH6) 및 제1항의 a)-i)그룹에서 선택된 물질의 겹합체를 함유하는 것을 특징으로 하는 제약학적 제제.
- 통상적인 제약학적 부가제, 보조제 및/또는 담체 물질과 함께 활성물질로서 전기한 항중 어느 한 항의 조성물로 특징되는 t-PA활성을 갖는 단백질을 기본으로 하는 의약.
- 제1항의 a)-i) 그룹중 최소한 하나의 물질과 함께 비글리코실화 t-PA를 적당한 제약학적 투여 형태로 전환시키는 것을 특징으로 하는, 제1항 내지 제18항중 어느 한 항의 제약학적 제제를 제조하는 방법.
- 제19항에 있어서 제약학적 투여 형태가 주사액 또는 동결건조물인 것을 특징으로 하는 방법.
- 제1항 내지 제18항중 어느 한 항의 제약학적 제제를 제조하는데 비글리코실화 t-PA를 사용하는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3942143A DE3942143A1 (de) | 1989-12-20 | 1989-12-20 | T-pa pro stabilisierung |
DEP39421430 | 1989-12-20 | ||
PCT/EP1990/002251 WO1991008766A1 (de) | 1989-12-20 | 1990-12-19 | t-PA pro STABILISIERUNG |
Publications (1)
Publication Number | Publication Date |
---|---|
KR920700684A true KR920700684A (ko) | 1992-08-10 |
Family
ID=6395926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019910700935A KR920700684A (ko) | 1989-12-20 | 1990-12-19 | t-PA pro의 안정화 |
Country Status (13)
Country | Link |
---|---|
US (1) | US5352453A (ko) |
EP (1) | EP0458939B1 (ko) |
JP (1) | JPH0657661B2 (ko) |
KR (1) | KR920700684A (ko) |
AT (1) | ATE103178T1 (ko) |
AU (1) | AU633684B2 (ko) |
CA (1) | CA2046929C (ko) |
DE (2) | DE3942143A1 (ko) |
FI (1) | FI96000C (ko) |
HU (2) | HUT59610A (ko) |
LV (1) | LV10199B (ko) |
NO (1) | NO305583B1 (ko) |
WO (1) | WO1991008766A1 (ko) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3942141A1 (de) * | 1989-12-20 | 1991-06-27 | Boehringer Mannheim Gmbh | K2p pro-stabilisierung |
WO1992018157A1 (de) * | 1991-04-16 | 1992-10-29 | Boehringer Mannheim Gmbh | Pharmazeutische verpackungseinheit enthaltend plasminogenaktivatoren zur mehrfachbolusgabe |
ATE173739T1 (de) * | 1992-04-30 | 1998-12-15 | Cor Therapeutics Inc | Stabile zusammensetzung von polypeptiden |
US6001480A (en) * | 1993-06-11 | 1999-12-14 | Zexel Corporation | Amorphous hard carbon film and mechanical parts coated therewith |
DE4405426A1 (de) * | 1994-02-21 | 1995-08-24 | Boehringer Mannheim Gmbh | Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate |
US6576265B1 (en) | 1999-12-22 | 2003-06-10 | Acell, Inc. | Tissue regenerative composition, method of making, and method of use thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5951220A (ja) * | 1982-08-02 | 1984-03-24 | Asahi Chem Ind Co Ltd | 新規なプラスミノ−ゲン・アクチベ−タ−およびその製法ならびにこれを含有する薬剤 |
EP0156169B1 (en) * | 1984-02-29 | 1991-12-18 | Asahi Kasei Kogyo Kabushiki Kaisha | An aqueous solution of a tissue plasminogen activator dissolved therein at an increased concentration and a method |
ZW14486A1 (en) * | 1985-07-29 | 1986-10-22 | Smithkline Beckman Corp | Pharmaceutical dosage unit |
EP0218112B1 (en) * | 1985-09-10 | 1992-12-09 | Eisai Co., Ltd. | Composition containing tissue plasminogen activator |
JPH0672105B2 (ja) * | 1985-10-02 | 1994-09-14 | 持田製薬株式会社 | 血栓溶解剤及びその製法 |
DE3537708A1 (de) * | 1985-10-23 | 1987-04-23 | Boehringer Mannheim Gmbh | Verfahren zur aktivierung von t-pa nach expression in prokaryonten |
US4777043A (en) * | 1985-12-17 | 1988-10-11 | Genentech, Inc. | Stabilized human tissue plasminogen activator compositions |
JPH0678241B2 (ja) * | 1986-04-02 | 1994-10-05 | エーザイ株式会社 | tPA医薬組成物 |
DE3718889A1 (de) * | 1987-06-05 | 1988-12-22 | Behringwerke Ag | Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin |
AU4187389A (en) * | 1988-08-02 | 1990-03-05 | Invitron Corporation | Method for preparing tpa compositions |
US4980165A (en) * | 1989-01-27 | 1990-12-25 | Genetics Institute, Inc. | Pharmaceutical formulations of plasminogen activator proteins |
DE3942141A1 (de) * | 1989-12-20 | 1991-06-27 | Boehringer Mannheim Gmbh | K2p pro-stabilisierung |
JPH0813750B2 (ja) * | 1990-03-01 | 1996-02-14 | 持田製薬株式会社 | 経口用トロンビン製剤 |
-
1989
- 1989-12-20 DE DE3942143A patent/DE3942143A1/de not_active Withdrawn
-
1990
- 1990-12-19 JP JP3501677A patent/JPH0657661B2/ja not_active Expired - Lifetime
- 1990-12-19 HU HU912742A patent/HUT59610A/hu unknown
- 1990-12-19 CA CA002046929A patent/CA2046929C/en not_active Expired - Lifetime
- 1990-12-19 AT AT91901285T patent/ATE103178T1/de not_active IP Right Cessation
- 1990-12-19 WO PCT/EP1990/002251 patent/WO1991008766A1/de active IP Right Grant
- 1990-12-19 DE DE91901285T patent/DE59005128D1/de not_active Expired - Lifetime
- 1990-12-19 AU AU70375/91A patent/AU633684B2/en not_active Ceased
- 1990-12-19 HU HU912742A patent/HU208637B/hu unknown
- 1990-12-19 EP EP91901285A patent/EP0458939B1/de not_active Expired - Lifetime
- 1990-12-19 KR KR1019910700935A patent/KR920700684A/ko not_active Application Discontinuation
-
1991
- 1991-08-06 US US07/741,483 patent/US5352453A/en not_active Expired - Lifetime
- 1991-08-09 NO NO913118A patent/NO305583B1/no not_active IP Right Cessation
- 1991-08-19 FI FI913909A patent/FI96000C/fi active
-
1993
- 1993-06-02 LV LVP-93-463A patent/LV10199B/lv unknown
Also Published As
Publication number | Publication date |
---|---|
AU633684B2 (en) | 1993-02-04 |
CA2046929A1 (en) | 1991-06-21 |
JPH0657661B2 (ja) | 1994-08-03 |
HU208637B (en) | 1993-12-28 |
NO913118D0 (no) | 1991-08-09 |
ATE103178T1 (de) | 1994-04-15 |
WO1991008766A1 (de) | 1991-06-27 |
FI96000B (fi) | 1996-01-15 |
NO305583B1 (no) | 1999-06-28 |
FI96000C (fi) | 1996-04-25 |
LV10199A (lv) | 1994-10-20 |
FI913909A0 (fi) | 1991-08-19 |
AU7037591A (en) | 1991-07-18 |
EP0458939B1 (de) | 1994-03-23 |
DE59005128D1 (de) | 1994-04-28 |
HUT59610A (en) | 1992-06-29 |
DE3942143A1 (de) | 1991-06-27 |
NO913118L (no) | 1991-08-09 |
LV10199B (en) | 1995-04-20 |
JPH03505465A (ja) | 1991-11-28 |
US5352453A (en) | 1994-10-04 |
EP0458939A1 (de) | 1991-12-04 |
HU912742D0 (en) | 1992-01-28 |
CA2046929C (en) | 1997-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6638913B1 (en) | Concentrated injection and infusion solution for intravenous administration | |
US6815435B2 (en) | Pharmaceutical compositions containing DDS compounds | |
RU2001108569A (ru) | Стабилизированная фармацевтическая композиция в лиофилизированной форме | |
KR920700681A (ko) | K₂P pro의 안정화 | |
KR920700684A (ko) | t-PA pro의 안정화 | |
Sveinbjørnsson et al. | Inhibition of establishment and growth of mouse liver metastases after treatment with interferon gamma and β-1, 3-d-glucan | |
RU2004133349A (ru) | Жидкий препарат, содержащий производное кампототецина, и фармацевтическая композиция, получаемая путем лиофилизации препарата | |
KR920700682A (ko) | 글리코실화된 t-PA의 안정화방법 | |
Käpyaho et al. | Stimulation of melanotic expression in murine melanoma cells exposed to polyamine antimetabolites | |
KR920700685A (ko) | K1K2P pro의 안정화 | |
VISTICA et al. | Amino acid conferred protection against melphalan: interference with leucine protection of melphalan cytotoxicity by the basic amino acids in cultured murine L1210 leukemia cells | |
Hosoi et al. | Sex difference in L-glutamine D-fructose-6-phosphate aminotransferase activity of mouse submandibular gland | |
Yoshida et al. | Optimal treatment schedule and antitumor spectrum of 4-carbamoylimidazolium 5-olate (SM-108) in murine tumors | |
JPS59130213A (ja) | 抗腫瘍方法及び組成物 | |
Choy et al. | L-Histidine inhibits the growth of Ehrlich ascites tumour | |
JPH04503525A (ja) | グリコシル化されていないt―PA誘導体K1K2Pproの製薬学的製剤および医薬品ならびに該製剤の製造方法 | |
JP2020002058A (ja) | イソプロピルメチルフェノールを含有する水性組成物 | |
JPH02504147A (ja) | 抗高脂血アミン |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |